Moran Wealth Management LLC Has $3.27 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Moran Wealth Management LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 0.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,047 shares of the medical technology company’s stock after acquiring an additional 34 shares during the quarter. Moran Wealth Management LLC’s holdings in Stryker were worth $3,268,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Centennial Bank AR lifted its holdings in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after acquiring an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in Stryker in the 3rd quarter valued at about $36,000. Hara Capital LLC bought a new position in Stryker during the third quarter worth $42,000. HBW Advisory Services LLC bought a new stake in shares of Stryker during the third quarter worth approximately $42,000. Finally, Grove Bank & Trust boosted its position in shares of Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock worth $24,825,275 over the last quarter. 5.90% of the stock is currently owned by company insiders.

Stryker Trading Up 1.1 %

Shares of SYK stock opened at $389.88 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market capitalization of $148.63 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 2.93 and a beta of 0.91. The company has a 50-day simple moving average of $365.91 and a two-hundred day simple moving average of $348.95. Stryker Co. has a 52-week low of $285.79 and a 52-week high of $398.20.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 earnings per share. Research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analyst Ratings Changes

SYK has been the topic of several analyst reports. Stifel Nicolaus reduced their target price on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Citigroup upped their price target on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Evercore ISI raised their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group boosted their price target on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $393.65.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.